In vitro inhibitory activity of the synthesized compounds against PARP-1^a.

Compd	IC50 (nM)	Compd	IC50 (nM)
Olaparib	30.38 ± 1.61	9a	101.6b ± 5.88
5a	336.0b ± 13.08	9b	174.3b ± 8.72
5b	218.3b ± 10.34	9c	313.7b ± 15.35
5c	354.1b ± 18.28	12a	39.07 ± 3.89
6a	55.96 ± 2.95	12b	89.69b ± 5.67
6b	64.67 ± 3.38	12c	27.89 ± 3.45
7a	128.4b ± 8.57	13a	102.3b ± 6.84
7b	79.06b ± 4.31	13b	44.16 ± 3.12
8a	32.49 ± 2.64	13c	45.64 ± 2.86
8b	154.66b ± 8.76	13d	485.3b ± 26.0
8c	403.2b ± 21.27

^aData are displayed as mean ± S. E. M. n = 3 (three independent repeats). Statistical analysis was carried out using one-way ANOVA followed by Dunnett post hoc test.

^bStatistically significant from Olaparib at p < 0.05.